Participated · Series B · Sep 2025

Sparrow Pharmaceuticals is a targeted cardiometabolic therapeutics company focused on type 2 diabetes that is resistant to standard care because of elevated cortisol. Its lead candidate, clofutriben, is a once-daily, oral selective 11β-HSD-1 inhibitor that lowers intracellular cortisol in key metabolic tissues. The drug has delivered improved glycemic control with a favorable safety and tolerability profile in early studies and is now being tested in the double-blind, Phase 2b CAPTAIN-T2D trial, with results expected in 2027. Beyond HbA1c reduction, clinical data suggest benefits on weight, blood pressure, lipids, bone metabolism, sleep and overall quality of life, addressing multiple facets of metabolic syndrome. The newly raised Series B funding will finance the Phase 2b program and further clinical development. Backing from premier life-science investors underscores confidence in Sparrow’s novel mechanism and market opportunity. The company remains pre-revenue as it advances its pipeline toward late-stage trials.

Participated · Series C · Apr 2025

Biolinq is a healthcare technology company developing precision intradermal biosensors to improve metabolic health. Its initial product is a wearable biosensor patch with an array of tiny electrochemical microsensors that measure glucose continuously just beneath the skin’s surface, providing real-time feedback via a color-changing indicator light on the upper forearm. The device is designed to combine glucose monitoring with activity and sleep information to support people with Type 2 diabetes not on insulin. Biolinq’s platform is positioned for future multi-analyte sensing capabilities and the company says it has spent the last decade developing the underlying technology. The company recently completed a US pivotal trial and submitted for regulatory review; its intradermal glucose sensor remains investigational and is not yet FDA cleared. A $100 million Series C will finance the company’s push from development toward commercial readiness as it pursues US regulatory approval; Biolinq is headquartered in San Diego. Biolinq develops a wearable patch that uses an array of tiny electrochemical microsensors placed in the intradermal space to measure glucose and relative activity from just beneath the skin surface. The device is designed for simplicity and user feedback, with an intuitive on-device display that notifies users when glucose is within or outside target ranges. Its sensor array is engineered for redundancy, reliability and multi-analyte capabilities without the use of introducer needles or bleeding. Biolinq describes the intradermal glucose sensor as investigational and not yet cleared or approved by the FDA. The company is headquartered in San Diego, CA. Proceeds from the completed financing will fund completion of a U.S. pivotal clinical trial this year and support a subsequent FDA submission. Biolinq is developing a wearable biosensor platform whose first product is a needle-free, intelligent continuous glucose sensor with a novel integrated display on the device. The device leverages semiconductor-industry innovation to miniaturize electrochemical sensors into a micro-array of miniature biosensors roughly 25 times smaller than conventional glucose sensors, enabling redundant measurements for reliability. Early feasibility studies demonstrated the microarray patch can track glucose continuously for up to seven days in people with diabetes. Biolinq’s approach includes multiplexed sensing capabilities and immediate biosensor feedback designed to simplify diabetes management and support future consumer health and wellness applications. The company is advancing clinical, regulatory, manufacturing and commercialization milestones to expand the sensing category. Financially, Biolinq completed a $100 million Series B financing, described as a record private capital raise in the continuous glucose monitoring space, with a broad syndicate of strategic and financial investors. Biolinq is developing a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes interstitial fluid to provide actionable health information. Its first commercial product aims to let people with diabetes continuously monitor blood glucose without the pain and hassle of traditional continuous glucose monitoring systems. The platform is wirelessly enabled and designed to simultaneously measure multiple biomarkers, enabling a pipeline of biomonitoring products. Biolinq plans to use new financing to support growth of its technology platform and to fund additional clinical studies. The company completed its first clinical study in 2018 and reports promising initial clinical results. Biolinq was founded in 2012 and is located in San Diego. Biolinq develops a skin-applied, minimally-invasive electrochemical biosensor platform that analyzes biomarkers in interstitial fluid. Its wirelessly-enabled, nickel-sized biosensor patch is designed to continuously monitor multiple biomarkers and its first commercial product targets blood glucose monitoring without the pain and hassle of traditional CGM systems. The company emphasizes factory calibration (no finger sticks), low cost-of-goods, high manufacturing uniformity, and ease of use. Biolinq intends to leverage its novel manufacturing approach to increase access to CGM and simplify diabetes management. The platform’s ability to simultaneously measure multiple biomarkers supports plans to build a pipeline of additional biomonitoring products. Biolinq was founded in 2012 (as Electrozyme, LLC) and is located in San Diego.

Participated · Series C · Apr 2025

Glycomine is a clinical-stage biotech based in San Carlos, California, focused on developing transformative therapies for rare orphan diseases. Its lead candidate, GLM101, is a first-in-class mannose-1-phosphate replacement therapy designed to deliver mannose-1-phosphate into cells and bypass disease-causing PMM2 mutations to restore N-glycosylation. GLM101 has received Orphan Drug Designation in the U.S. and E.U., and Rare Pediatric Disease and Fast Track designations in the U.S. The company has enrolled more than 20 patients across Europe and the U.S. in an ongoing Phase 2 open-label study and has initiated dosing in pediatric patients. Data from the Phase 2 open-label study showed an average 11.9-point improvement on the ICARS among nine adult and adolescent patients over 24 weeks, providing clinical proof of concept for improvement in ataxia. Glycomine recently announced a $115 million Series C financing to support advancing GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study later this year. Glycomine is a biotechnology company based in San Carlos, California, developing therapies for orphan diseases. Its lead candidate, GLM101, is a mannose-1-phosphate substrate replacement therapy designed to deliver mannose-1-phosphate intracellularly to bypass PMM2 enzyme deficiency and restore N-glycosylation. Preclinical studies have shown GLM101 can restore disrupted glycosylation pathways in PMM2-CDG. GLM101 has received Orphan Drug Designation in the U.S. and Europe and Rare Pediatric Disease Designation in the U.S. Glycomine plans to use the Series B proceeds to advance GLM101 into initial clinical trials and confirm clinical potential across PMM2-CDG genotypes. The company focuses on replacement therapies targeted to clinically relevant cellular compartments for rare metabolic and protein-misfolding disorders. Glycomine focuses on developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding. The company’s approach combines replacement therapies—substrates, enzymes, or proteins—with delivery vehicles made of bio-nanomaterials or ligands to target molecules to the cell interior of relevant organs. Glycomine intends to use the new capital to advance its substrate replacement therapy for PMM2‑CDG (CDG‑1a) into early-stage clinical studies. The company raised $33m in a Series B financing led by Novo Holdings A/S. In connection with the financing, Peter McWilliams, Ph.D., moved from acting CEO to full-time CEO. Kenneth Harrison, Ph.D., of Novo Ventures and Chris Starr, Ph.D., joined the company’s board. Glycomine is a San Francisco, CA–based biotechnology company developing a new generation of replacement therapies for rare monogenic disorders of metabolism and protein misfolding. Its approach combines replacement therapies—substrates, enzymes, or proteins—with intracellular delivery vehicles consisting of bio‑nanomaterials or targeting ligands to deliver molecules into clinically relevant organs. The company is led by CEO Agnes Rafalko, PhD, with Christopher Starr, PhD serving as Executive Chairman. Glycomine raised $12m in a Series A financing to advance its pipeline. The company intends to use the funds to complete IND‑enabling preclinical studies and initiate clinical studies of a substrate replacement therapy in patients with Congenital Disorder of Glycosylation Type Ia (CDG‑Ia). Proceeds will also be used to accelerate discovery efforts toward an enzyme replacement therapy for N‑glycanase deficiency (Ngly1).

Participated · Series B · Jan 2025

Atalanta Therapeutics develops RNA interference (di-siRNA) therapies to enable durable, selective gene silencing throughout the brain and spinal cord. The company’s wholly owned pipeline targets Huntington’s disease, genetic epilepsies, severe chronic pain and other neurological diseases, alongside partnered programs with Genentech. Its lead candidates are ATL-201 for KCNT1-related epilepsy and ATL-101 for Huntington’s disease, both showing strong preclinical reductions in target gene expression, durability, and tolerability. Atalanta is progressing these programs toward IND submissions in 2025 and plans Phase 1 trials to reach clinical proof-of-concept. The company is headquartered in Boston and emphasizes delivering oligonucleotide therapies to previously inaccessible CNS regions. Atalanta Therapeutics is developing branched siRNA, a novel oligonucleotide architecture designed to silence gene expression in the central nervous system. The technology was licensed from the University of Massachusetts Medical School and is being applied across multiple neurodegenerative diseases. The company announced strategic collaborations with Biogen and Genentech to develop RNAi therapeutics for targets including HTT for Huntington’s disease and additional CNS targets related to Parkinson’s and Alzheimer’s disease. Under those collaborations Atalanta is eligible to receive development and milestone payments and royalties on any resulting products. Leadership and founding scientists named in the article include CEO Alicia Secor and founders Anastasia Khvorova, Craig Mello, and Neil Aronin, with senior scientific and business officers listed. Atalanta raised $110 million in a Series A financing announced alongside these collaborations.

Participated · Equity · Jan 2025

Alleviant Medical develops the Alleviant System, a minimally invasive, no-implant atrial shunt designed to relieve excess pressure by creating a temporary connection between the left and right atrial chambers. The procedure is one-time and leaves no permanent implant behind. The Alleviant System has received U.S. FDA Breakthrough Device designation for both major forms of heart failure. The company is running pivotal clinical programs across the full spectrum of heart failure, with ALLAY-HF evaluating patients with preserved ejection fraction (HFpEF) and on track to finalize enrollment within the next year. The new program, ALLAY-HFrEF, will investigate patients with reduced ejection fraction (HFrEF) and is planned as a prospective sham-controlled pivotal trial. Alleviant is headquartered in Austin, Texas. Alleviant Medical is developing the Alleviant System, a minimally invasive, implant-free interatrial shunt intended to decompress the left atrium and treat chronic heart failure. The company has FDA Breakthrough Device designation (2021) and received an IDE approval in November 2022 to support clinical investigation. Clinical studies to date have enrolled 38 heart failure patients, showing functional and symptomatic improvement with shunt durability confirmed through six months and sustained improvement through 12 months. Alleviant will use the new financing to fund ALLAY-HF, a global, prospective, multicenter, randomized, sham-controlled, double-blinded, adaptive pivotal trial enrolling 400–700 patients with HFpEF and HFmrEF. The trial’s composite primary endpoint analysis will be conducted at one year and is designed to demonstrate safety and effectiveness of the Alleviant System. The company is headquartered in Austin, Texas and is backed by a syndicate of institutional and strategic healthcare investors.